Our advocacy efforts are being heard. We are very excited to hear that Cablivi (caplacizumab) will be submitted for reconsideration by Sanofi! This resubmission is a critical waypoint on our quest for access. We have work to do to prepare our own submission to decision makers, and we need your help now. Click the survey link below.
What a resubmission means is the national agency (CADTH Canadian Agency for Drugs and Technologies in Health) will decide again whether Cablivi should be reimbursed by the provinces. This will also happen in Quebec with their health technology body.
In addition to reviewing the pharma submission, and seeking clinician feedback, CADTH values patient perspectives. As such, Answering TTP Foundation will prepare a submission on behalf of Canadian TTP patients. Our submission will focus on the patient’s perspective to tell these governing bodies why we need Cablivi reimbursed, and its impact on patients.
To do so, we've created a short survey. Please complete the survey ASAP and circulate the link to other patients (or caregivers) so that we can collect as much anonymous information about as many TTP experiences as possible accross Canada.
We are a very small TTP community in Canada. It is crucial that as many patient voices are heard as possible. We want to make sure that Cablivi will be reimbursed by the provinces so that it is available to our physicians to treat the next TTP crisis.